Patents Examined by Mark L. Shibuya
-
Patent number: 11976057Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.Type: GrantFiled: October 4, 2021Date of Patent: May 7, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Edward Brnardic, Michael Bury, Rodolfo Cadilla, Jon Collins, Yu Guo, Anthony Handlon, Huijie Li, Yue Li, Daniel Paone, Christie Schulte, Barry Shearer, Maben Ying, Guosen Ye, Huichang Zhang, Millard Hurst Lambert, III
-
Patent number: 11951083Abstract: Systems, compositions, and methods are disclosed for developing and delivering therapeutically effective 14,15-epoxyeicosatrienoic acid (14,15-EET) analogs, for example for pain management or treatment. Of particular interest are intermediate salts.Type: GrantFiled: July 18, 2022Date of Patent: April 9, 2024Assignee: Cytometix, Inc.Inventors: John R. Falck, Lane Brostrom
-
Patent number: 11890345Abstract: The present application relates to compositions comprising vitamins and/or minerals and a polyphenolic matrix having increased stability and bioavailability. The polyphenolic matrix may comprise a polyphenolic extract, an emulsifier and a binder. The polyphenolic extract may be a fruit peel extract. The present application further relates to uses and methods using the compositions of the application.Type: GrantFiled: November 2, 2021Date of Patent: February 6, 2024Assignee: ProMedXInnovations Inc.Inventor: Fabrizio Di Stefano
-
Patent number: 11865095Abstract: Provided herein are combinations comprising difluoromethylornithine (DFMO), or an ionic form thereof, and a compound of the following structural formula: or a protonated form thereof, wherein values for the variables (e.g., a, b, c, d, e, n, R1, R2, X) are described herein. The combinations can provide combination drug therapy in a single pharmaceutical dosage form, and be used, for example, for the treatment of cancer.Type: GrantFiled: September 30, 2021Date of Patent: January 9, 2024Assignee: Aminex Therapeutics, Inc.Inventor: Mark R. Burns
-
Patent number: 11795176Abstract: The invention relates to crystalline forms of Alpha-1062 gluconate. In one aspect, the invention relates to a crystalline solid form of Alpha-1062 gluconate (Form A), wherein said crystalline form has prominent peaks at 3.61, 10.98, 14.41 and 18.44 degrees 2-theta (±0.2) in a powder X-ray diffraction pattern. The invention further relates to methods for manufacturing crystalline forms and compositions comprising said crystalline forms.Type: GrantFiled: January 13, 2022Date of Patent: October 24, 2023Assignee: Alpha Cognition Inc.Inventor: Fred D. Sancilio
-
Patent number: 11718600Abstract: The present technology is directed to methods of inhibiting or modulating p97 and compounds and compositions useful in such methods. Diseases and conditions that can be treated with the compounds and compositions of the present technology include, but are not limited to, antibacterial infection, antiviral infection, cancer and neurodegenerative disorders susceptible to treatment by modulation of p97.Type: GrantFiled: April 11, 2019Date of Patent: August 8, 2023Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Donna M. Huryn, Peter Wipf
-
Patent number: 11712474Abstract: Disclosed are means of stimulating systemic immunity and reduction of post-surgery tumor metastasis through the concurrent intralymphatic inhibition of NR2F6 and treatment with cannabidiol. In some embodiments NR2F6 is inhibited by high pressure transient delivery of short interfering RNA into tumor draining lymph nodes concurrent with systemic administration of cannabidiol. This combination may be performed together with means that induce immunogenic tumor cell death. Through the combination of immunogenic cell death and immune stimulation, the invention provides a means of enhancing the abscopal effect and in some embodiments to cause immunological mediated destruction primary and secondary neoplasia.Type: GrantFiled: September 29, 2020Date of Patent: August 1, 2023Assignee: Regen Biopharma, Inc.Inventors: Thomas Ichim, David Koos
-
Patent number: 11712439Abstract: This document provides methods and materials involved in identifying and treating mammals having a cancer resistant to BET inhibitors. For example, methods and materials for administering one or more AKT inhibitors in combination with one or more BET inhibitors to mammals identified as having a cancer resistant to treatment with one or more BET inhibitors in the absence of AKT inhibitors are provided.Type: GrantFiled: August 9, 2018Date of Patent: August 1, 2023Assignees: Mayo Foundation for Medical Education and Research, Shanghai Changhai HospitalInventors: Haojie Huang, Yinghao Sun, Shancheng Ren
-
Patent number: 11697638Abstract: Described herein are crystalline fumarate salts having a Formula I, pharmaceutical formulations comprising the same, methods for their production, and uses thereof, Formula I comprising: wherein each R1 is independently selected from protium and deuterium; each R2 is independently selected from protium and deuterium; each R3 is independently selected from protium and deuterium; and each R4 is independently selected from protium and deuterium; and wherein the compound has a PXRD pattern comprising characteristic peaks at 19.2±0.2 and 24.7±0.2 degrees 2-theta.Type: GrantFiled: September 8, 2021Date of Patent: July 11, 2023Assignee: Small Pharma LtdInventors: Peter Rands, Marie Claire Layzell
-
Patent number: 11672781Abstract: The invention provides a pharmaceutical composition comprising sodium lauryl sulfate, hydroxypropyl methylcellulose (HPMC), a copolymer of vinylpyrrolidone and vinyl acetate, and a therapeutically effective amount of metaxalone or a pharmaceutically acceptable salt thereof. Related processes and methods are also disclosed.Type: GrantFiled: May 6, 2019Date of Patent: June 13, 2023Assignee: PRANA BIOSCIENCES INCInventors: Prabu Nambiar, Binesh Prabhakar, Geevarghese Easo
-
Patent number: 11661396Abstract: The present invention provides novel crystalline forms of zuclomiphene citrate. Specific crystalline forms provided by the present invention include zuclomiphene citrate Forms APO-I, APO-II, APO-III, and APO-IV. Also provided are pharmaceutical compositions including the zuclomiphene citrate crystalline forms, processes for the preparation thereof and the use of these forms in the treatment of a disorder selected from the group including osteoporosis, bone fractures, loss of bone mineral density (BMD) and hot flashes in a subject suffering therefrom.Type: GrantFiled: January 21, 2021Date of Patent: May 30, 2023Assignee: Apotex Inc.Inventors: Fabio E. S. Souza, Mohammed Abdul Raheem, Yajun Zhao, Siva Ramarao Kakani, Minh T. N. Nguyen, Alexander J. Stirk, Allan W. Rey, Stuart P. Green
-
Patent number: 11628168Abstract: The present disclosure provides application of a compound in conformity with a general formula I and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease and a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.Type: GrantFiled: June 5, 2019Date of Patent: April 18, 2023Assignees: CHINESE PLA GENERAL HOSPITAL, SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT COMPANY, LTD.Inventors: Kunlun He, Xiaojian Gao, Chunlei Liu, Zeyu Zhang, Xin Li, Chen Li, Yunfu Luo, Maoyi Lei, Junmiao Li, Yiwei Wang
-
Patent number: 10981907Abstract: Polycyclic derivatives of formula I wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.Type: GrantFiled: November 27, 2018Date of Patent: April 20, 2021Assignee: Syngenta Participations AGInventors: Andrew Edmunds, Michel Muehlebach, Pierre Marcel Jung, Andre Jeanguenat
-
Patent number: 10961242Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.Type: GrantFiled: February 6, 2020Date of Patent: March 30, 2021Assignee: LegoChem Biosciences, Inc.Inventors: Dae Yon Lee, Sang Eun Chae, Eun Mi Jung, Eun Hye Yang, Yoon Jeong Choi, Chul-Woong Chung, Ju Hyun Shin, Yun Ki Kim, Hyun Jin Kwon, Jeong Hee Ryu, Eun Hye Ban, Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae
-
Patent number: 10961187Abstract: Novel substituted N-acetyl-L-cysteine (NAC) derivatives and related compounds and methods of using these compounds for the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of, or involving, the Central Nervous System (CNS), including schizophrenia adrenoleukodystrophy, mitochondrial diseases (e.g. Leigh syndrome, Alpers' disease, and MELAS), Huntington's disease, trichotillomania, HIV-associated neurocognitive disorder, hypoxic-ischemic encephalopathy, drug craving, and drug addiction.Type: GrantFiled: June 17, 2019Date of Patent: March 30, 2021Assignee: Promentis Pharmaceuticals, Inc.Inventors: Michael Neary, James Nieman, Steven Tanis, Daniel Lawton, Garry Smith
-
Patent number: 10960003Abstract: The present invention provides pyrazole pyrimidine derivatives which inhibit Casein kinase I (CKI) and/or Interleukin-1 receptor-associated kinase 1 (IRAKI) and methods of their manufacture, compositions comprising them and uses thereof in methods of treating malignant disease and disorders and methods for treating inflammatory diseases and disorders.Type: GrantFiled: August 12, 2019Date of Patent: March 30, 2021Assignee: BioTheryX, Inc.Inventors: Yinon Ben Neriah, Guy Brachya, Ido Burstain, Waleed Minzel, Irit Snir-Alkalay, Joseph Vacca, Dansu Li
-
Patent number: 10954217Abstract: Provided herein, inter alia, are compounds and methods of treating diseases including cancer, neurological disease, alcohol withdrawal, depression and anxiety, and neuropathic pain.Type: GrantFiled: April 29, 2017Date of Patent: March 23, 2021Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Stephen F. Martin, James J. Sahn, Kathryn Taylor Linkens
-
Patent number: 10954232Abstract: The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-?, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.Type: GrantFiled: June 30, 2017Date of Patent: March 23, 2021Assignee: HANMI PHARMACEUTICAL CO., LTD.Inventors: Kyung Ik Lee, Young Hee Jung, Ji Young Song, Seung Ah Jun
-
Patent number: 10946016Abstract: The present invention provides a solid form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibit desirable characteristics for the same.Type: GrantFiled: June 22, 2018Date of Patent: March 16, 2021Assignee: Celgene CAR LLCInventor: Mei Lai
-
Patent number: 10941115Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have anti-inflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.Type: GrantFiled: July 10, 2019Date of Patent: March 9, 2021Assignee: Oxular Acquisitions LimitedInventors: Thomas Matthew Baker, Matthew Colin Thor Fyfe, Geraint Jones, Stephen Malcolm Thom